Clinical trial
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or…
NCT00482378 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00482378 |
|---|---|
| Title | Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain |
| Official title | An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm, Pain |
| Intervention type | Drug, Radiation |
| Interventions | Pamidronate, Zoledronic acid, Sm 153 lexidronam |
| Enrollment | 39 |
| Start date | Mar 21, 2005 |
| Primary completion | May 22, 2007 |
| Completion | Dec 2, 2008 |
| First posted | Jun 5, 2007 |
| Last update posted | Aug 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: